Research & Development
US FDA approves SFA Therapeutics' clinical trial for treatment of 'the appearance of the structure of skin with plaques due to psoriasis'
30 June 2020 -

The United States Food and Drug Administration (FDA) has approved United States-based SFA Therapeutics Inc to conduct a clinical trial, officially referred to as an IND, intended for the treatment of 'the appearance of the structure of skin with plaques due to psoriasis', it was reported on Monday.

The company plans to expand the assessment of one of its five microbiome-derived drugs, SFA002, in this new trial.

The trial is being conducted in 30 patients and is an open-label clinical trial in patients with mild-to-moderate psoriasis. It will enrol 15 patients into treatment with an initial formulation of SFA002 and an additional 15 patients for the treatment with a second formulation. The company is treating the patients with the formulations for three months, after which patients will be observed for an additional three months. The company is planning to start patient recruitment in the autumn of 2020. It is likely to finalise the SFA002 formulation and proceed into a randomised controlled clinical trial.

Login
Username:

Password: